Tesfaye Madebo

Dr. Tesfaye Madebo

University of Stavanger, Stavanger, Rogaland, Norway
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YSYvette Louise Schein
Yvette Louise Schein
TMTesfaye Madebo
Tesfaye Madebo
HAHilde Elise Andersen
Hilde Elise Andersen
TATrude Margrete Arnesen
Trude Margrete Arnesen
ARAnne Margarita Dyrhol Riise
Anne Margarita Dyrhol Riise
BWBrita Askeland Winje
Brita Askeland Winje
Successful treatment of latent tuberculosis infection (LTBI) is essential to reduce tuberculosis (TB) incidence rates in low-burden countries. This study measures treatment completion and determinants of non-completion of LTBI treatment in Norway in 2016. This prospective cohort study included all individuals notified with LTBI treatment to the Norwegian Surveillance System for Infectious Diseases (MSIS) in 2016. We obtained data from MSIS and from a standardized form that was sent to health care providers at the time of patient notification to MSIS. We determined completion rates. Pearson’s chi squared test was used to study associations between pairs of categorical variables and separate crude and multivariable logistic regression models were used to identify factors associated with treatment completion and adverse drug effects. We obtained information on treatment completion from 719 of the 726 individuals notified for LTBI treatment in 2016. Overall, 91% completed treatment. Treatment completion was highest in the foreign-born group [foreign-born, n = 562 (92%) vs Norwegian-born, n = 115 (85%), p = 0.007]. Treatment completion did not differ significantly between prescribed regimens (p = 0.124). Adverse events were the most common reason for incomplete treatment. We found no significant differences in adverse events when comparing weekly rifapentine (3RPH) with three months daily isoniazid and rifampicin (3RH). However, there were significantly fewer adverse events with 3RPH compared to other regimens (p = 0.037). Age over 35 years was significantly associated with adverse events irrespective of regimen (p = 0.024), whereas immunosuppression was not significantly associated with adverse events after adjusting for other variables (p = 0.306). Treatment under direct observation had a significant effect on treatment completion for foreign-born (multivariate Wald p-value = 0.017), but not for Norwegian-born (multivariate Wald p-value = 0.408) individuals. We report a very high treatment completion rate, especially among individuals from countries with high TB incidence. The follow-up from tuberculosis-coordinators and the frequent use of directly observed treatment probably contributes to this. Few severe adverse events were reported, even with increased age and in individuals that are more susceptible. While these results are promising, issues of cost-effectiveness and targeting treatment to individuals at highest risk of TB are important components of public health impact.

8 December 2010 in Integrative Cancer Therapies
Verified
Journal Article
Open access
PDF file
HGHuiru Guo
Huiru Guo
JLJia Xiang Liu
Jia Xiang Liu
LXLing Xu
Ling Xu
TMTesfaye Madebo
Tesfaye Madebo
JBJan P. A. Baak
Jan P. A. Baak
Background: Targeted therapy (TT), chemotherapy, and traditional Chinese medicine herbal treatment (TCM) can improve the prognosis of advanced pulmonary adenocarcinoma patients. Their independent prognostic value is unknown. Objective: To study whether TCM improves survival in stage IV pulmonary adenocarcinoma patients with platinum-based chemotherapy (PBT), or combined PBT and second-line TT. Methods: Retrospective analysis of 133 fully ambulant clinical outpatients treated with PBT alone or PBT with/without second-line TT, with/without TCM. Univariate (Kaplan—Meier) and multivariable (Cox model) survival analysis were performed, using disease-specific mortality as an endpoint. Results: Gender (P = .002), TT (P < .0001), and TCM (P < .0001) had univariate prognostic value but not age, radiotherapy, or TCM syndrome differentiation (P > .10). TCM herbal treatment (P < .0001) and TT (P = .03) had multivariable independent prognostic value. TCM-treated patients (n = 103, PBT+TT+TCM+ = 62; PBT+TT−TCM+ =41) had 88% 1-year overall survival rate with median survival time (MST) of 27 months, contrasting 27% 1-year overall survival and MST of 5.0 months for non-TCM-treated (n = 30) patients. Patients with chemotherapy/TT/TCM (PBT+TT+TCM+, n = 62), TCM without TT (PBT+TT−TCM+, n = 41), or chemotherapy only (PBT+TT−TCM−, n = 30), had 1-year survival rates of 94%, 78%, and 27% respectively; for these 3 groups, respectively, MST was not reached (MST of 30.9 months), 22.6, and 5.0 months (P < .0001). Conclusions: TCM herbal treatment may improve survival of stage IV pulmonary adenocarcinoma patients treated with chemotherapy without or with second-line TT. This warrants formal phase 1 and 2 trials and ultimately properly designed prospective clinical validation trials with adequate methodology developed for data collection.

5 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
TMTesfaye Madebo
Tesfaye Madebo
MBMitra Bemanian
Mitra Bemanian
JVJørn Henrik Vold
Jørn Henrik Vold
RCRanadip Chowdhury
Ranadip Chowdhury
CAChrister Frode Aas
Christer Frode Aas
LFLars T. Fadnes
Lars T. Fadnes
People with severe substance use disorder (SUD) have a higher burden of micronutrient deficiency compared with the general population. The aim of this study was to investigate vitamin B12 status and risk factors of deficiency related to substance use, opioid agonist therapy (OAT), as well as hepatitis C infection and liver fibrosis. In this prospective cohort study, participants were recruited from outpatient OAT and SUD clinics in western Norway, and assessed annually with a clinical interview and exam, including venous blood sampling. Data were collected between March 2016 and June 2020, and a total of 2451 serum vitamin B12 measurements from 672 participants were included. The median serum vitamin B12 concentration was 396 (standard deviation 198) pmol/L at baseline, 22% of the population had suboptimal levels (<300 pmol/L) and 1.2% were deficient at baseline (<175 pmol/L). No clear associations were seen with substance use patterns, but liver disease and younger age were associated with higher vitamin B12 levels. Although the majority of participants had satisfactory vitamin B12 levels, about a fifth had suboptimal levels that might or might not be adequate for metabolic needs. Future studies could investigate potential gains in interventions among patients with suboptimal but non-deficient levels.

19 March 2026 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
FSFrigg Å. Sommervoll
Frigg Å. Sommervoll
HHHenrik Horndalsveen
Henrik Horndalsveen
DSDag Einar Sommervoll
Dag Einar Sommervoll
JKJussi Koivunen
Jussi Koivunen
THTarje Onsøien Halvorsen
Tarje Onsøien Halvorsen
TMTesfaye Madebo
Tesfaye Madebo
Background: Impaired pulmonary function is common among patients with lung cancer and may negatively affect health-related quality of life (HRQoL). The primary objective of the present sub-study of the DART-trial was to assess the overall quality of life changes during treatment and stratified by the presence of Chronic Obstructive Pulmonary Disease (COPD).Methods: The investigator-initiated DART trial (NCT04392505) included patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy followed by durvalumab. Baseline pulmonary function was measured by spirometry, and patients were stratified by FEV1/FVC <70% (COPD) or ≥70% (non-COPD). HRQoL was assessed regularly using the EORTC QLQ-C30 and QLQ-LC13 questionnaires at screening and during treatment. A difference in mean score of ≥10 was defined as clinically significant.Results: A total of 86 patients initiated durvalumab and completed at least one HRQoL assessment; pulmonary function data were available for 64 patients. For the overall cohort, quality of life scores remained stable throughout treatment. Patients with COPD consistently reported lower global health scores than those with preserved lung function. The global health score among patients with COPD was not significantly different at end of treatment compared to baseline, however significantly lower than patients without COPD. Symptom trajectories across QLQ-C30 scales were stable in both groups. Dyspnoea was more prevalent among patients with COPD. In the LC13 module, no clinically significant differences were observed except for dyspnoea, which was consistently higher among patients with COPD.Interpretation: The HRQoL remained stable during chemoradiotherapy and durvalumab treatment in stage III NSCLC patients. Impaired lung function was associated with modestly lower HRQoL, though larger studies are needed to confirm subgroup effects.

31 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
LTLise Margrete Thomassen
Lise Margrete Thomassen
EAElaheh Javadi Arjmand
Elaheh Javadi Arjmand
KDKarl T. Druckrey-Fiskaaen
Karl T. Druckrey-Fiskaaen
EFEinar Furulund
Einar Furulund
JVJørn Henrik Vold
Jørn Henrik Vold
FGfor the ATLAS4LAR and FruktBAR study group
for the ATLAS4LAR and FruktBAR study group
Background/Objectives: People with opioid dependence often experience elevated inflammatory markers and poor dietary habits. Evidence from other populations suggests that higher fruit and vegetable intake may reduce inflammation. This multicenter randomized controlled trial investigates whether offering a daily supplementation of 250 mL of fruit smoothie for 16 weeks to people undergoing opioid agonist treatment (OAT) can reduce inflammation biomarkers. Methods: 319 individuals were randomized to receive either a daily supplement of 250 mL of fruit smoothie in addition to standard OAT or standard OAT alone over 16 weeks. The primary outcome was the log-transformed change in high-sensitivity C-reactive protein (hs-CRP). Secondary outcomes included changes in cytokines (IL-8, IL-1RA, and MCP-1) and leukocyte counts. Results: No between-group differences were observed in changes in hs-CRP levels (0.96 (0.77; 1.21) mg/L), leukocytes (0.99 (0.93; 1.05)109/L), IL-8 (1.10 (0.84; 1.46) pg/mL), MCP-1 (0.94 (0.80; 1.11) pg/mL), and IL-1RA (1.06 (0.91; 1.23) pg/mL). High levels of inflammatory markers were observed at baseline in both the intervention group and the control group. Conclusions: After 16 weeks of offering fruit smoothie supplementation in patients receiving OAT, we did not detect a between-group reduction in inflammation markers such as hs-CRP, IL-8, MCP-1, IL-1RA, and leukocyte counts, under the achieved level of delivery and exposure. Nonetheless, persistently high levels of inflammatory markers were observed in this study.

1 September 2026 in Patient Education and Counseling
Verified
Journal Article
Open access
MRMarte Morønning Ruud
Marte Morønning Ruud
RSRebekka Salte
Rebekka Salte
MSMargrethe Aase Schaufel
Margrethe Aase Schaufel
PGPål Gulbrandsen
Pål Gulbrandsen
ØFØystein Fløtten
Øystein Fløtten
SWSaul J. Weiner
Saul J. Weiner